Fitbit, Humana expand partnership

Humana and Fitbit are expanding their partnership to allow more than 5 million of the insurer’s members to potentially have access to Fitbit wellness solutions or health coaching.

The companies announced the deal on Wednesday, Sept. 19. According to a press release, Humana has selected Fitbit Care as a preferred health coaching solution for its employer group segment. The deal allows more than 5 million Humana members to potentially have access to the platform. 

“The health coaching solution from Fitbit Care will provide Humana members across the U.S. with the support and guidance to help members make the lifestyle changes necessary to better manage chronic and complex diseases, while creating stronger connections between the participants and entire care team,” the release stated.

Fitbit Care is a new platform that combines health coaching and virtual care. The platform serves as a support system for users as they work to achieve their health goals. It also allows users to communicate directly with a coach and create personalized plans that work best for them.

Humana and Fitbit have been partners since 2013. The companies said the decision to expand the partnership reflects their “continued commitment to driving healthy behavior change and reducing the occurrence of preventable chronic disease, such as diabetes and heart disease.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.